Evidence map›Paper›PMID 38251362›Full record

ArticlePathogens (Basel, Switzerland)2024

Analysis of a Cohort of 165 Pediatric Patients with Human Bocavirus Infection and Comparison between Mono-Infection and Respiratory Co-Infections: A Retrospective Study.

Alice Caporizzi, Federica Ravidà, Sara Barneschi, Maria Moriondo, Francesco Nieddu, Silvia Boscia, Mariangela Stinco, Silvia Ricci, Sandra Trapani

Open access · goldAbstract readComparative Study
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Alice CaporizziPostgraduate School of Pediatrics, University of Florence, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Federica RavidàPostgraduate School of Pediatrics, University of Florence, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Sara BarneschiPostgraduate School of Pediatrics, University of Florence, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Maria MoriondoDivision of Immunology, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Francesco NiedduDivision of Immunology, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Silvia BosciaDivision of Immunology, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Mariangela StincoPediatric Unit, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Silvia RicciDivision of Immunology, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.
Sandra TrapaniPediatric Unit, Meyer Children's Hospital IRCCS, Viale Pieraccini 24, 50139 Florence, Italy.ORCID 0000-0003-1105-1500
Meyer Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHuman Bocavirus (HBoV) is mainly associated with respiratory tract infections. However, its role as respiratory pathogen is not fully understood for a high co-infection rate in symptomatic patients and a significant HBoV detection rate in asymptomatic subjects. This study aimed to describe a large cohort of children with HBoV infection and to compare HBoV mono-infection and co-infections.

methodsWe retrospectively reviewed data from 165 children admitted to Meyer Children's Hospital IRCCS from March 2022 to March 2023 with the diagnosis of HBoV infection, detected using Reverse Transcription qPCR from nasal swabs. Thereafter, we compared patients with HBoV mono-infection (Group A) and those with HBoV co-infections (Group B) in terms of disease severity, established by the length of stay (LOS), the requirement of Pediatric Intensive Care Unit (PICU), and advanced respiratory support (ARS).

resultsThe median age was 1.5 years; 80% of patients presented with respiratory symptoms. The discharge rate from the emergency department (ED) within 24 h was 42.4%. Most cases (57.6%) were hospitalized, and 7.3% were admitted to PICU due to respiratory failure. Group A comprised 69 patients, and Group B 96 children (95% viral co-infections, 2% bacterial, 3% viral and bacterial). Group A and Group B were similar in hospitalization rate but differed significantly in LOS (median 3 vs. 5 days) and requirement of PICU admission (0 vs. 12 patients,

conclusionsHBoV should be considered a relevant respiratory pathogen especially in viral co-infections. Patients with HBoV co-infections have a higher risk of necessitating advanced respiratory support with more PICU admission and longer LOS; a previous respiratory disease puts them at a higher risk of longer hospitalization.

Indexed as

CoinfectionHuman bocavirusParvoviridae InfectionsRespiratory Tract InfectionsChildChild, PreschoolFemaleHospitalizationHumansInfantIntensive Care Units, PediatricLength of StayMaleRetrospective Studieschildrenco-infectionhuman bocavirusmono-infectionrespiratory tract infection

Identifiers

PMID38251362
PMCPMC10821073
OpenAlexW4390689569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.